Form 4: Korro Bio Director Bermingham Acquires Stock Options

Director Nessan Bermingham acquired 5,190 stock options in Korro Bio, Inc. on June 11, 2024.

Summary

• Nessan Bermingham, a director of Korro Bio, Inc., filed a Form 4 on June 12, 2024, reporting a transaction.
• On June 11, 2024, Bermingham acquired 5,190 stock options with an exercise price of $42.19.
• The options vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.
• Following the transaction, Bermingham directly owns 5,190 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports a transaction. The acquisition of options by a director can be seen as mildly positive, suggesting confidence in the company.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock options as a positive signal.

Key Dates